Intuitive Surgical (NASDAQ:ISRG) has received FDA approval for its Fluorescence Imaging Vision System, called Firefly, as an optional feature for its robotic surgical system da Vinci Xi. Upon approval, the company will start shipping Firefly installed in the da Vinci Xi systems. The company launched da Vinci Xi in April 2014, followed by its FDA clearance.
Firefly will help surgeons locate the leakage of blood, which usually happens beneath the tissue layers, without using any heavy machinery. The platform has the ability to simplify surgical procedures as it synchronizes a camera with fluorescent color, endoscope and laser-based illuminator. Surgeons can use this system to locate the vasculatures, the arrangement of blood vessels that are usually present beneath the tissue layers.
In my original analysis I noted that since da Vinci Xi has broader capabilities than earlier generation da Vinci platforms, the Xi version is considered a technological leap forward in replacing large-incision abdominal open surgeries with a minimally invasive approach. The adoption rate of da Vinci Xi is expected to increase with Firefly installed in it.
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.